Stocks | | | Some of the most popular dividend-paying stocks are known as dividend aristocrats. Aristocrats are basically people that are known for being the best and noblest in all of the land, so associating that word with stocks has significant power. Read the Full Story |
|
|
Markets | | | Tesla (TSLA) is riding a wave of positive sentiment that may carry it to new highs later this year. The stock is up 5% in the last day, 20% in the last two weeks, and 180% over the last seven months and took Ford's spot as a top-three automaker by market-cap. The short-sellers are bleeding.
Analyst... Read the Full Story |
|
Markets | | | Boston based Vertex Pharmaceuticals (NASDAQ: VRTX) got some positive headlines on Wednesday as Oppenheimer raised their price target for the stock to $265, about a 20% premium to where shares opened the session. Read the Full Story |
|
From Our PartnersThe NASDAQ stock exchange is abundant with emerging growth biotech stocks, but there is one company that is on our radar that is targeting the most aggressive type of brain cancer that was developed at the largest cancer treatment and research institute in the world. They recently IPO’d at $4 per share and they are preparing to begin their Phase II clinical trials. | | Click here for more details. |
|
Markets | | | Constellation Is Well-Positioned For Today’s Consumer Market
The analysts turned cautious on Constellation Brands (STZ) in the second half of 2019 but their fears were overblown. Although the general consensus is bullish, fully half the analysts that cover the stock lowered their price target... Read the Full Story |
|
Markets | | |
The news is starting to come in about the holiday shopping season, and though we're hearing about plenty of records, the earnings news isn't what you'd call good all over. Word out of JCPenney (NYSE: JCP) and Kohl's (NYSE: KSS) say that same-store shopping sales were on the decline over this time ... Read the Full Story |
|
From Our Partners2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year. | | Click Here to Download the FREE Report |
|
The Early Bird Stock Of The Day Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. | | View Today's Stock Pick |
|
